Actively Recruiting
Liposomal Irinotecan and Apatinib in ES-SCLC
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2024-12-27
30
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
CONDITIONS
Official Title
Liposomal Irinotecan and Apatinib in ES-SCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Expected survival of at least 12 weeks
- At least one measurable tumor lesion according to RECIST version 1.1
- Have failed first-line or second-line treatment for small cell lung cancer
You will not qualify if you...
- Previous treatment with systemic drugs targeting VEGF or VEGFR, such as ranibizumab, fipronib, apatinib, anlotinib, lenvatinib, sunitinib, or sorafenib
- Active or uncontrolled severe infection with CTCAE grade 2 or higher, or antibiotic treatment within 2 weeks before enrollment
- Conditions that affect oral medication absorption, including inability to swallow, nausea, vomiting, chronic diarrhea, or intestinal obstruction
- Considered unsuitable for the study by the doctors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
X
Xian Zhong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here